Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E9.35 EPS (ttm)32.40 Insider Own0.10% Shs Outstand172.80M Perf Week2.36%
Market Cap52.33B Forward P/E9.29 EPS next Y32.59 Insider Trans-1.98% Shs Float164.86M Perf Month3.33%
Income5.88B PEG10.42 EPS next Q7.98 Inst Own89.90% Short Float2.72% Perf Quarter-4.09%
Sales14.42B P/S3.63 EPS this Y44.80% Inst Trans-4.55% Short Ratio2.24 Perf Half Y1.02%
Book/sh72.61 P/B4.17 EPS next Y-1.27% ROA22.00% Target Price318.07 Perf Year35.59%
Cash/sh22.34 P/C13.56 EPS next 5Y0.90% ROE44.50% 52W Range215.77 - 374.99 Perf YTD2.07%
Dividend- P/FCF7.90 EPS past 5Y20.50% ROI30.50% 52W High-19.24% Beta0.54
Dividend %- Quick Ratio1.50 Sales past 5Y8.20% Gross Margin87.50% 52W Low40.36% ATR8.34
Employees7400 Current Ratio1.70 Sales Q/Q1.30% Oper. Margin51.00% RSI (14)47.42 Volatility2.45% 2.88%
OptionableYes Debt/Eq0.48 EPS Q/Q13.00% Profit Margin40.80% Rel Volume0.46 Prev Close301.45
ShortableYes LT Debt/Eq0.36 EarningsApr 22 BMO Payout0.00% Avg Volume2.00M Price302.86
Recom2.70 SMA20-2.02% SMA50-1.66% SMA2006.28% Volume914,700 Change0.47%
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Jun-02-20 10:18AM  
Jun-01-20 09:52AM  
May-29-20 08:47AM  
08:00AM  
May-28-20 09:00AM  
07:30AM  
May-26-20 12:55PM  
06:44AM  
05:37AM  
May-23-20 07:36AM  
May-22-20 06:04PM  
09:05AM  
06:07AM  
May-21-20 02:49PM  
May-20-20 09:23AM  
08:58AM  
May-19-20 09:48AM  
07:30AM  
May-18-20 02:47PM  
07:30AM  
May-15-20 10:18AM  
May-14-20 10:00AM  
09:34AM  
09:28AM  
May-13-20 01:16PM  
10:09AM  
10:05AM  
May-12-20 04:01PM  
10:03AM  
10:00AM  
May-11-20 05:40PM  
11:58AM  
10:26AM  
10:07AM  
09:52AM  
May-08-20 10:33AM  
08:59AM  
08:51AM  
08:50AM  
08:50AM  
07:57AM  
May-07-20 03:28PM  
11:03AM  
10:40AM  
10:33AM  
09:14AM  
09:09AM  
May-06-20 11:48AM  
11:33AM  
10:51AM  
10:49AM  
10:23AM  
May-05-20 03:26PM  
03:11PM  
11:21AM  
May-04-20 07:57PM  
05:59PM  
03:12PM  
10:55AM  
10:38AM  
10:26AM  
May-01-20 06:55AM  
Apr-30-20 03:08PM  
Apr-28-20 11:16AM  
10:28AM  
08:51AM  
Apr-27-20 05:52PM  
04:06PM  
01:05PM  
09:53AM  
Apr-26-20 08:26AM  
Apr-24-20 10:19AM  
06:00AM  
Apr-23-20 05:50PM  
03:49PM  
03:26PM  
01:55PM  
10:47AM  
03:02AM  
Apr-22-20 11:24PM  
06:26PM  
04:32PM  
03:36PM  
10:23AM  
10:20AM  
09:50AM  
09:28AM  
09:26AM  
09:20AM  
09:07AM  
08:32AM  
08:03AM  
07:13AM  
06:21AM  
06:00AM  
Apr-21-20 07:36PM  
04:37PM  
Apr-20-20 05:45PM  
10:09AM  
Apr-19-20 11:28AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM